Humana SVP Sells $399,880 in Stock (HUM)
Humana (NYSE:HUM) SVP Brian P. Leclaire sold 3,250 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $123.04, for a total value of $399,880.00. Following the completion of the sale, the senior vice president now directly owns 13,196 shares in the company, valued at approximately $1,623,636. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Humana (NYSE:HUM) traded up 0.84% during mid-day trading on Monday, hitting $124.22. 570,002 shares of the company’s stock traded hands. Humana has a 52-week low of $90.19 and a 52-week high of $134.93. The stock’s 50-day moving average is $124.7 and its 200-day moving average is $117.3. The company has a market cap of $19.161 billion and a P/E ratio of 18.49.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 30th. The company reported $2.19 earnings per share for the quarter, meeting the analysts’ consensus estimate of $2.19. During the same quarter last year, the company posted $2.63 earnings per share. Analysts expect that Humana will post $7.73 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Raymond James reiterated an “outperform” rating on shares of Humana in a research note on Thursday, August 7th. They now have a $128.00 price target on the stock, up previously from $123.00. Separately, analysts at Leerink Swann raised their price target on shares of Humana to $140.00 in a research note on Friday, August 1st. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Humana in a research note on Thursday, July 31st. They now have a $126.00 price target on the stock. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. Humana currently has an average rating of “Hold” and a consensus target price of $126.00.
Humana Inc (NYSE:HUM) is a health care company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.